Table 3.
Study/ClinicalTrials.gov identifier status | Population | Phase/primary endpoint | Regimens |
---|---|---|---|
CA209-374/NCT02596035: recruiting | Untreated and pretreated adv/met ccRCC and nccRCC | IIIB−IV/safety | ccRCC cohort: nivo 240 mg IV q2w nccRCC cohort: nivo 240 mg IV q2w Brain metastases cohort: nivo 240 mg IV q2w |
NCT02575222: recruiting | Nonmet stage II−IV ccRCC eligible for nephrectomy | I/safety and tolerability | Three doses of nivo 3 mg/kg q2w prior to nephrectomy |
ADAPTeR/NCT02446860: recruiting | Met RCC eligible for nephrectomy | II/safety: biomarker analysis | Biopsy of primary tumor, followed by 8 weeks of nivo, followed by nephrectomy, then postoperatively until patient is no longer deriving clinical benefit |
NCT02595918: not yet recruiting | High-risk nonmet kidney cancer | I/safety-biomarker analysis | Three doses of nivo and complete surgery |
Adv, advanced; met, metastatic; RCC, renal cell carcinoma; ccRCC, clear-cell renal cell carcinoma; nccRCC, nonclear-cell renal cell carcinoma; nivo, nivolumab; q2w, every 2 weeks.